USE OF ANTITHROMBIN IN EXTRACORPOREAL MEMBRANE OXYGENATION

• US 20140194360A1
• Filed: 08/02/2013
• Published: 07/10/2014
• Est. Priority Date: 08/03/2012
• Status: Active Grant

• Current Assignee: rEVO Biologics, Inc. (Agence des Participations de l’Etat)
• Original Assignee: rEVO Biologics, Inc. (Agence des Participations de l’Etat)
• Inventors: Frieling, Johan, Lowry, Simon
• Granted Patent: US 9,511,087 B2
• Time in Patent Office: Days
• US Class Current: 514/14.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

In one aspect, the disclosure provides methods of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®.

Claims

1. A method of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation, the method comprising:

administering to a subject having extracorporeal membrane oxygenation a therapeutically effective amount of antithrombin to suppress blood clotting and/or prevent hemorrhage.

2. The method of claim 1, wherein the antithrombin has a high mannose glycosylation pattern.

3. The method of claim 1 or claim 2, wherein the antithrombin has a high fucose glycosylation pattern.

4. The method of any one of claims 1-3, wherein the antithrombin comprises GalNac (N-acetylgalactosamine).

5. The method of any one of claims 1-4, wherein the antithrombin is transgenically produced antithrombin.

6. The method of claim 5, wherein the antithrombin is transgenically produced in a goat.

7. The method of any one of claims 1-6, wherein the antithrombin is ATryn®

.

8. The method of any one of claims 1-7, wherein the antithrombin is administered at a dose of 6 units per kg.

9. The method of any one of claims 1-8, wherein the antithrombin is administered at a dose of 80 units per kg.

10. The method of any one of claims 1-8, wherein the antithrombin is administered at a dose of 295 units per kg.

11. The method of any one of claims 1-8, wherein the antithrombin is administered at a dose sufficient to maintain a level of antithrombin activity present in the blood at the time of initiation of extracorporeal membrane oxygenation.

12. The method of any one of claims 1-11, wherein the antithrombin is administered in one dose.

13. The method of any one of claims 1-11, wherein the antithrombin is administered by a bolus followed by continuous infusion.

14. The method of any one of claims 1-13, further comprising administering heparin.